Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026)

Cogent Biosciences (COGT) has 10 years of Accumulated Expenses data on file, last reported at $6.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 69.18% year-over-year to $6.2 million in Q1 2026; TTM through Mar 2026 was $6.2 million, a 69.18% increase from a year earlier, with the FY2025 full-year figure at $15.7 million, down 62.64% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.2 million, down from $15.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for COGT reached as high as $42.1 million in Q4 2024 and fell as low as $1.5 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $10.5 million across 5 years, with a median of $7.7 million in 2024.
• Across the five-year window, Accumulated Expenses soared 1000.48% in 2023 and tumbled 84.81% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $17.9 million in 2022, then slumped by 44.79% to $9.9 million in 2023, then soared by 326.7% to $42.1 million in 2024, then tumbled by 62.64% to $15.7 million in 2025, then sank by 60.58% to $6.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $6.2 million in Q1 2026, $15.7 million in Q4 2025, and $10.5 million in Q3 2025.